The vaccine candidate is slated to use the recombinant vesicular stomatitis virus (rVSV) technology used as the basis for Merck’s Ervebo Ebola Zaire virus vaccine, which was the first such vaccine to be approved for use in humans, according to a news release. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Dept. of Health and Human Services, to provide funding for the collaboration.
About Sean Whooley
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at firstname.lastname@example.org.